The next orthopaedics megamerger
The orthopaedics sector has seen several sizeable mergers over the past decade. Might it see more?
Another robot deal for J&J shows up lack of Verb results
Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
Diagnostics specialists win the US device approval race
The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.
A change of the guard for the world’s biggest cancer companies
Roche is set to lose its crown as the largest oncology player to the newly merged Bristol-Myers Squelgene, while Astrazeneca is forecast to streak up the rankings.
Triple meeting – clinical data, and competition, loom for Mirati
Mirati pulls a rabbit out of its hat, but the conference will serve up three new competitors too.
Uncovering biopharma’s hidden treasures
Which deals accidentally brought in the biggest biopharma blockbusters? A new analysis by Vantage reveals all.
Esmo 2019 – Clovis is running out of waves to catch
In prostate cancer Clovis could be adopting a more realistic regulatory stance with its Parp than Astrazeneca and Merck & Co. In the long run will it matter much?
Esmo 2019 – Targeted bile duct treatment pits Incyte against Agios
The rare disease bile duct cancer is set to be carved up by genetic subtype, and will see two targeted treatments filed soon.
Go or no go? Novartis eyes a big new growth driver
The biggest approval decision in October will involve Novartis’s eye asset Beovu, while Biogen and Alkermes face a key verdict in MS.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.